Medivation (MDVN) Shares are Up 19.64%

Medivation (MDVN) : Traders are bullish on Medivation (MDVN) as it has outperformed the S&P 500 by a wide margin of 25.83% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 20.43%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 19.64% in the last 1 week, and is up 25.57% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 18.38% and the fifty day Moving Average is 26.12%. Medivation, Inc. is up 32.53% in the last three month period. Year-to-Date the stock performance stands at 66.22%.

Medivation (MDVN) : The highest short term price target forecast on Medivation (MDVN) is $82 and the lowest target price is $40. A total of 14 equity analysts are currently covering the company. The average price of all the analysts is $71.82 with a standard deviation of $12.35.


Medivation (NASDAQ:MDVN): stock turned positive on Friday. Though the stock opened at $80.24, the bulls momentum made the stock top out at $80.35 level for the day. The stock recorded a low of $80.21 and closed the trading day at $80.35, in the green by 0.14%. The total traded volume for the day was 7,546,241. The stock had closed at $80.24 in the previous days trading.

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.